SZ-3

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 208333

CAS#: 25477

Description: SZ-3 is a first-in-class small-molecule inhibitor of cofilin to target secondary complications of ICH, mainly neuroinflammation. SZ-3 showed no effect on neuronal/microglial survival but prevented microglia from LPS-induced inflammation by decreasing NO and preventing neurotoxicity. and showed anti-inflammatory activities.


Chemical Structure

img
SZ-3
CAS# 25477

Theoretical Analysis

MedKoo Cat#: 208333
Name: SZ-3
CAS#: 25477
Chemical Formula: C29H37N3O3
Exact Mass: 475.28
Molecular Weight: 475.630
Elemental Analysis: C, 73.23; H, 7.84; N, 8.83; O, 10.09

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: SZ3, sz-3, sz3

IUPAC/Chemical Name: 1-(4-(Bis(5-(tert-butyl)-2-hydroxybenzyl)amino)phenyl)urea

InChi Key: OUKWSSCBNGZGDW-UHFFFAOYSA-N

InChi Code: InChI=1S/C29H37N3O3/c1-28(2,3)21-7-13-25(33)19(15-21)17-32(24-11-9-23(10-12-24)31-27(30)35)18-20-16-22(29(4,5)6)8-14-26(20)34/h7-16,33-34H,17-18H2,1-6H3,(H3,30,31,35)

SMILES Code: O=C(N)NC1=CC=C(N(CC2=CC(C(C)(C)C)=CC=C2O)CC3=CC(C(C)(C)C)=CC=C3O)C=C1

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 475.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Walker CK, Roche JK, Sinha V, Roberts RC. Substantia nigra ultrastructural pathology in schizophrenia. Schizophr Res. 2018 Jul;197:209-218. doi: 10.1016/j.schres.2017.12.004. Epub 2017 Dec 21. PMID: 29274737; PMCID: PMC6013319.


2: Alaqel SI, Dlamini S, Almarghalani DA, Shettigar A, Alhadidi Q, Kodithuwakku SH, Stary C, Tillekeratne LMV, Shah ZA. Synthesis and Development of a Novel First-in-Class Cofilin Inhibitor for Neuroinflammation in Hemorrhagic Brain Injury. ACS Chem Neurosci. 2022 Apr 6;13(7):1014-1029. doi: 10.1021/acschemneuro.2c00010. Epub 2022 Mar 18. PMID: 35302736.


3: Lopez-Campos JL, Casas-Maldonado F, Torres-Duran M, Medina-Gonzálvez A, Rodriguez-Fidalgo ML, Carrascosa I, Calle M, Osaba L, Rapun N, Drobnic E, Miravitlles M. Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. Arch Bronconeumol (Engl Ed). 2021 Jan;57(1):42-50. English, Spanish. doi: 10.1016/j.arbres.2020.04.014. Epub 2020 Jul 14. PMID: 32680720.


4: Zheng T, Yang Z, Gui D, Liu Z, Wang X, Dai X, Liu S, Zhang L, Gao Y, Chen L, Sheng D, Wang Y, Diwu J, Wang J, Zhou R, Chai Z, Albrecht-Schmitt TE, Wang S. Overcoming the crystallization and designability issues in the ultrastable zirconium phosphonate framework system. Nat Commun. 2017 May 30;8:15369. doi: 10.1038/ncomms15369. PMID: 28555656; PMCID: PMC5459948.


5: Gentile FS, Mackrodt WC, Allan NL, Dovesi R. Predicted strong spin-phonon interactions in Li-doped diamond. Phys Chem Chem Phys. 2020 Sep 23;22(36):20612-20617. doi: 10.1039/d0cp03182h. PMID: 32966424.


6: Cang HX, Han YP, Zhou JX, Bi RC. The space experiment of protein crystallization aboard the Chinese spacecraft SZ-3. Microgravity Sci Technol. 2003;14(3):13-6. doi: 10.1007/BF02870939. PMID: 14658452.


7: Seo HW, Hung TM, Na M, Jung HJ, Kim JC, Choi JS, Kim JH, Lee HK, Lee I, Bae K, Hattori M, Min BS. Steroids and triterpenes from the fruit bodies of Ganoderma lucidum and their anti-complement activity. Arch Pharm Res. 2009 Nov;32(11):1573-9. doi: 10.1007/s12272-009-2109-x. PMID: 20091270.


8: Hu XQ, Liu JJ, Qiu KM, Fan TX, Zhang YX, Rong ZG, Zhang LJ. [New method study of sites vicarious calibration for SZ-3/CMODIS]. Guang Pu Xue Yu Guang Pu Fen Xi. 2009 May;29(5):1153-9. Chinese. PMID: 19650442.


9: Zhang X, Zhang Q, Wang T, Ma L, Yu Y, Chen L. Hydrodeoxygenation of lignin- derived phenolic compounds to hydrocarbons over Ni/SiO2-ZrO2 catalysts. Bioresour Technol. 2013 Apr;134:73-80. doi: 10.1016/j.biortech.2013.02.039. Epub 2013 Feb 22. PMID: 23500562.


10: Makutani S, Yoshioka T, Uchida H, Tanaka T, Yoshimura H, Ohishi H, Iwasaki S, Ide K, Ueda K, Maeda M. [Experimental study of esophageal covered stent for prevention of migration: use of clay to simulate stenosis of the esophagogastric junction or anastomosis site]. Nihon Igaku Hoshasen Gakkai Zasshi. 2000 Jul;60(8):434-8. Japanese. PMID: 10965749.